Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Locally advanced or metastatic NSCLC

• Measurable disease

• ECOG PS 0 or 1

Exclusion Criteria:

• Known CNS metastasis

• Pre-existing autoimmune or antibody mediated disease